An AIDS vaccine, made by the National Institute of Health in Bethesda is tested for its efficacy. The proportion of people without antibodies to Adenovirus-5 (Ad-5) varies dramatically across proposed study sites. The vaccine is tested on its potential to reduce high level antibody response to Ad-5.